ADMA Biologics, Inc.

ADMA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$197,673-$28,239-$65,904-$71,648
Dep. & Amort.$8,045$8,332$7,113$5,496
Deferred Tax-$84,280$0$0$221
Stock-Based Comp.$13,616$6,187$5,215$3,488
Change in WC-$18,539-$10,123-$18,285-$51,680
Other Non-Cash$2,157$32,643$12,353$1,755
Operating Cash Flow$118,672$8,800-$59,508-$112,369
Investing Activities
PP&E Inv.-$8,226-$4,771-$13,911-$13,511
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.-$349-$210$0$0
Investing Cash Flow-$8,575-$4,981-$13,911-$13,511
Financing Activities
Debt Repay.-$60,000-$23,601$51,714-$34
Stock Issued$7,494$0$64,645$121,144
Stock Repurch.$0-$1,415$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$5,796-$13,973-$7,507-$62
Financing Cash Flow-$58,302-$38,989$108,852$121,048
Forex Effect$0$0$0$0
Net Chg. in Cash$51,795-$35,170$35,432-$4,832
Supplemental Information
Beg. Cash$51,352$86,522$51,089$55,921
End Cash$103,147$51,352$86,522$51,089
Free Cash Flow$110,097$3,819-$73,419-$125,880